Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

[News]

Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

More... (http://www.news-medical.net/news/20120109/Circadian-initiates-VGX-100-Phase-1-trial-in-advanced-solid-tumours.aspx)